NASDAQ:CERS Cerus (CERS) Stock Price, News & Analysis $2.38 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.33▼$2.4650-Day Range$1.67▼$2.3952-Week Range$1.21▼$3.08Volume735,399 shsAverage Volume1.27 million shsMarket Capitalization$440.04 millionP/E RatioN/ADividend YieldN/APrice Target$3.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cerus alerts: Email Address Cerus MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside61.1% Upside$3.83 Price TargetShort InterestHealthy3.69% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 2 Articles This WeekInsider TradingAcquiring Shares$9,675 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.09) to ($0.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.91 out of 5 starsMedical Sector431st out of 936 stocksSurgical & Medical Instruments Industry56th out of 101 stocks 3.3 Analyst's Opinion Consensus RatingCerus has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCerus has only been the subject of 1 research reports in the past 90 days.Read more about Cerus' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.69% of the outstanding shares of Cerus have been sold short.Short Interest Ratio / Days to CoverCerus has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Cerus has recently decreased by 4.34%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCerus does not currently pay a dividend.Dividend GrowthCerus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERS. Previous Next 2.7 News and Social Media Coverage News SentimentCerus has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cerus this week, compared to 2 articles on an average week.Search Interest2 people have searched for CERS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cerus to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerus insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,675.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Cerus is held by insiders.Percentage Held by Institutions78.37% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cerus' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cerus are expected to grow in the coming year, from ($0.09) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerus is -14.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerus is -14.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerus has a P/B Ratio of 8.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cerus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Cerus Stock (NASDAQ:CERS)Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.Read More CERS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CERS Stock News HeadlinesJune 21, 2024 | businesswire.comCerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood TransfusionJune 14, 2024 | businesswire.comCerus Corporation Celebrates World Blood Donor Day 2024July 27, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...May 22, 2024 | businesswire.comCerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor ConferenceMay 5, 2024 | markets.businessinsider.comCerus’s Strong Q1 Growth and Promising INTERCEPT Technology Drive Buy RatingMay 4, 2024 | finance.yahoo.comCerus First Quarter 2024 Earnings: EPS Misses ExpectationsMay 3, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Joint (JYNT) and Cerus (CERS)May 3, 2024 | finance.yahoo.comCerus Corp (CERS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...July 27, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...May 3, 2024 | finance.yahoo.comQ1 2024 Cerus Corp Earnings CallMay 3, 2024 | finance.yahoo.comCerus Corporation (NASDAQ:CERS) Q1 2024 Earnings Call TranscriptMay 2, 2024 | investorplace.comCERS Stock Earnings: Cerus Meets EPS, Misses Revenue for Q1 2024May 2, 2024 | sfgate.comCerus: Q1 Earnings SnapshotMay 2, 2024 | finance.yahoo.comCerus Corp (CERS) Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss NarrowsMay 2, 2024 | businesswire.comCerus Corporation Announces First Quarter 2024 Financial ResultsApril 26, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Cerus (CERS), MiMedx Group (MDXG)April 18, 2024 | finance.yahoo.comCerus Corporation (NASDAQ:CERS) is a favorite amongst institutional investors who own 64%April 18, 2024 | businesswire.comCerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024See More Headlines Receive CERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:CERS CUSIP15708510 CIK1020214 Webwww.cerus.com Phone(925) 288-6000Fax925-288-6001Employees625Year Founded1991Price Target and Rating Average Stock Price Target$3.83 High Stock Price Target$5.00 Low Stock Price Target$2.50 Potential Upside/Downside+63.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,490,000.00 Net Margins-19.27% Pretax Margin-19.16% Return on Equity-58.65% Return on Assets-15.14% Debt Debt-to-Equity Ratio1.29 Current Ratio2.41 Quick Ratio1.72 Sales & Book Value Annual Sales$156.37 million Price / Sales2.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book8.10Miscellaneous Outstanding Shares184,890,000Free Float178,604,000Market Cap$434.49 million OptionableOptionable Beta1.20 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. William M. Greenman (Age 57)President, CEO & Director Comp: $1.04MMr. Kevin D. Green (Age 52)VP of Finance & CFO Comp: $607.53kMr. Vivek K. Jayaraman (Age 49)Chief Operating Officer Comp: $696.68kMs. Chrystal Jensen (Age 53)Chief Legal Officer & General Counsel Comp: $571.49kDr. Richard J. Benjamin MBChB (Age 64)Ph.D., Chief Medical Officer Comp: $603.68kDr. Laurence M. Corash (Age 80)Co-Founder & Chief Scientific Officer Comp: $697.77kMs. Lori L. RollVP of Administration & Corporate SecretaryMr. Matthew M. NotarianniSenior Director of Investor RelationsLainie CortenVice President of Global MarketingMs. Alicia GoodmanChief Human Resources OfficerMore ExecutivesKey CompetitorsAtrionNASDAQ:ATRIAnika TherapeuticsNASDAQ:ANIKOraSure TechnologiesNASDAQ:OSURUtah Medical ProductsNASDAQ:UTMDCardiovascular SystemsNASDAQ:CSIIView All CompetitorsInsiders & InstitutionsARK Investment Management LLCSold 1,645,012 shares on 7/26/2024Ownership: 10.763%Bank of New York Mellon CorpBought 57,073 shares on 7/26/2024Ownership: 0.332%Easterly Investment Partners LLCSold 176,333 shares on 7/25/2024Ownership: 0.021%Secure Asset Management LLCBought 15,600 shares on 7/24/2024Ownership: 0.008%Sumitomo Mitsui Trust Holdings Inc.Sold 252,460 shares on 7/19/2024Ownership: 4.056%View All Insider TransactionsView All Institutional Transactions CERS Stock Analysis - Frequently Asked Questions How have CERS shares performed this year? Cerus' stock was trading at $2.16 on January 1st, 2024. Since then, CERS stock has increased by 10.2% and is now trading at $2.38. View the best growth stocks for 2024 here. How were Cerus' earnings last quarter? Cerus Co. (NASDAQ:CERS) announced its earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. The biotechnology company had revenue of $38.37 million for the quarter, compared to the consensus estimate of $36.40 million. Cerus had a negative net margin of 19.27% and a negative trailing twelve-month return on equity of 58.65%. What is William M. (Obi) Greenman's approval rating as Cerus' CEO? 15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Cerus' major shareholders? Cerus' top institutional investors include ARK Investment Management LLC (10.76%), Sumitomo Mitsui Trust Holdings Inc. (4.06%), Assenagon Asset Management S.A. (0.64%) and Bank of New York Mellon Corp (0.33%). Insiders that own company stock include William Mariner Greenman, Vivek K Jayaraman, Kevin Dennis Green, Chrystal Jensen, Carol Moore, Richard J Benjamin, Chrystal Menard, Daniel N Swisher Jr, Ann Lucena, Hua Shan, Gail Schulze and Laurence M Corash. View institutional ownership trends. How do I buy shares of Cerus? Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cerus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE) and Immunomedics (IMMU). This page (NASDAQ:CERS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerus Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
